首页> Molecular therapy : the journal of the American Society of Gene Therapy> First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.

First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers.

导出 OA

翻译打印收藏纠错

第一作者： Fenne L,Komdeur

第一单位： Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

作者： Fenne L,Komdeur ^[1] ; Amrita,Singh ^[2] ; Stephanie,van de Wall ^[2] ; Janneke J M,Meulenberg ^[3] ; Annemarie,Boerma ^[2] ; Baukje Nynke,Hoogeboom ^[2] ; Sterre T,Paijens ^[1] ; Cesar,Oyarce ^[2] ; Marco,de Bruyn ^[1] ; Ed,Schuuring ^[4] ; Joke,Regts ^[2] ; Ruben,Marra ^[2] ; Naomi,Werner ^[4] ; Jessica,Sluis ^[1] ; Ate G J,van der Zee ^[1] ; Jan C,Wilschut ^[2] ; Derk P,Allersma ^[5] ; Coba J,van Zanten ^[5] ; Jos G W,Kosterink ^[5] ; Annelies,Jorritsma-Smit ^[4] ; Refika,Yigit ^[1] ; Hans W,Nijman ^[1] ; Toos,Daemen ^[6]

作者单位： Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ^[1] Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ^[2] ViciniVax BV, Meditech Center, Groningen, the Netherlands. ^[3] Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ^[4] Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ^[5] Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Electronic address: c.a.h.h.daemen@umcg.nl. ^[6]

关键词 Vvax001 alphavirus replicon vaccine cervical intraepithelial neoplasia human papillomavirus immunotherapy recombinant Semliki Forest virus vector therapeutic vaccine